股票CFDs仅限于MT5账号类型。每个平台提供的平均点差是每日更新的，反映了前一天的平均值。虽然FxPro试图在所有交易时间内提供有竞争力的点差，但客户应注意这些点差可能会因潜在市场条件的影响而有所不同。以上内容仅供参考。建议客户查看我们的经济日历中的重要新闻公告，以上均可能会导致点差扩大以及其他情况。

以上点差适用于正常交易条件，根据“商业条款与条件”，FxPro有权根据市场条件对以上点差做调整。

Trade AbCellera Biologics Inc

AbCellera is a Canadian biotechnology company headquartered in Vancouver, built around a proprietary antibody discovery platform that it licenses to pharmaceutical and biotech partners developing new drug candidates. Listed on Nasdaq under the ticker ABCL.O, the company gained widespread recognition during the COVID-19 pandemic as the discoverer of bamlanivimab, an antibody treatment developed in partnership with Eli Lilly and Company, which brought both revenue and visibility to a business that had previously operated largely below mainstream investor radar.

The underlying business model is distinctive: rather than advancing drugs through the full clinical pipeline itself, AbCellera acts as an upstream discovery partner, taking royalties and milestones as its partners progress candidates towards commercialisation. That royalty-driven structure gives the company long-term revenue potential largely decoupled from the operational complexity of running clinical trials, though near-term income can be lumpy and heavily dependent on partner development timelines.

Please note this is marketing communication, not recommendation or advice.

请注意，本材料只是一种市场传播，不应被视为投资意见或建议。